MDXG (MiMedx Group) FFO


MDXG MiMedx Group Inc MDXG
57 GF Score
Price $3.82
GF Value $6.96
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group FFO?

FFO (Funds from operations) only applies to REITs.

MDXG
57GF Score
MiMedx Group Inc MDXG
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $3.82 is trading 45.2% below its estimated GF Value™ of $6.96. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • FFO:
  • GF Value™: $6.96 vs. price of $3.82 (45.2% below fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score

Get the complete analysis for MDXG

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price
$6.96
GF Value